Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement

RationaleThe study of the different effects on brain metabolism between typical and atypical antipsychotics would aid in understanding their mechanisms of action. Clozapine is of special interest, since it is one of the most effective antipsychotic drugs and demonstrates a distinctive mechanism of action in pre-clinical studies with respect to typical neuroleptics.ObjectiveTo study the differences in cerebral activity induced by clozapine as compared to those produced by haloperidol.Methods[18F]Fluoro-deoxy-glucose (FDG)-positron emission tomography (PET) scans were obtained in the resting condition before and after 6 months of treatment with clozapine in 22 treatment-resistant patients with schizophrenia. Before inclusion, patients had been chronically treated with classical drugs, and all of them received haloperidol during the last month. Data were analyzed with statistical parametric mapping (SPM′99) methods, comparing pre-treatment and post-treatment conditions. The association between the changes in symptom scores and metabolism was also assessed to corroborate the functional relevance of possible metabolic changes.ResultsClozapine decreased prefrontal and basal ganglia activity, and increased occipital metabolism, including primary and association visual areas. The change in negative symptoms was related with the decrease of basal ganglia activity; the improvement in disorganization related to the metabolic decrease in the motor area, and the change in positive symptoms was associated to the increase of activity in the visual area.ConclusionsThese results show that haloperidol and clozapine produce different patterns of metabolic changes in schizophrenia. Compared to the haloperidol baseline, clozapine inhibited the metabolic activity of the prefrontal and motor cortical regions and basal ganglia and induced a higher activation of the visual cortex. The improvement in disorganization, negative and positive syndromes with clozapìne may be respectively associated with metabolic changes in the motor area, basal ganglia, and visual cortex.

[1]  G. Pearlson,et al.  Structural evaluation of the prefrontal cortex in schizophrenia. , 1998, The American journal of psychiatry.

[2]  M S Buchsbaum,et al.  PET and MRI of the thalamus in never-medicated patients with schizophrenia. , 1996, The American journal of psychiatry.

[3]  A. Deutch,et al.  Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  Philip D. Harvey,et al.  Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. , 1998, Archives of general psychiatry.

[5]  G. Sedvall,et al.  D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. , 1994, The Journal of clinical psychiatry.

[6]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[7]  Monte S. Buchsbaum,et al.  Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia , 1996, Schizophrenia Research.

[8]  H. Meltzer,et al.  Clozapine: New research on efficacy and mechanism of action , 1989, European archives of psychiatry and neurological sciences.

[9]  M M Mesulam,et al.  Thalamic connections of the insula in the rhesus monkey and comments on the paralimbic connectivity of the medial pulvinar nucleus , 1984, The Journal of comparative neurology.

[10]  B. Cohen,et al.  The thalamus as a site of action of antipsychotic drugs. , 1996, The American journal of psychiatry.

[11]  H. Fibiger,et al.  Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine , 1992, Neuroscience.

[12]  P. Fischer,et al.  In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol , 1999, Psychopharmacology.

[13]  J. Ehrhardt,et al.  Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. , 1994, Science.

[14]  William Byne,et al.  Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. , 2002, The American journal of psychiatry.

[15]  Carol A Tamminga,et al.  Functional effects of antipsychotic drugs: comparing clozapine with haloperidol , 2003, Biological Psychiatry.

[16]  S. Potkin,et al.  Clozapine effects on glucose metabolic rate in striatum and frontal cortex. , 1994, The Journal of clinical psychiatry.

[17]  Claude Nahmias,et al.  Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by position emission tomography (PET) , 1993, Schizophrenia Research.

[18]  M S Buchsbaum,et al.  Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. , 1999, The American journal of psychiatry.

[19]  V. M. Rodríguez,et al.  Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study , 1997, Schizophrenia Research.

[20]  H. Möller,et al.  D2-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects , 1998, Pharmacopsychiatry.

[21]  H. Barbas,et al.  Architecture and cortical connections of the prefrontal cortex in the rhesus monkey. , 1992, Advances in neurology.

[22]  V. M. Rodríguez,et al.  Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A99mTc-HMPAO study , 1997, Psychiatry Research: Neuroimaging.

[23]  M. Desco,et al.  Cerebral metabolism and risperidone treatment in schizophrenia , 2003, Schizophrenia Research.

[24]  B. Bunney,et al.  Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study , 1990, Journal of neurochemistry.

[25]  B. Morris,et al.  Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol , 2002, Neuropharmacology.

[26]  N. Andreasen,et al.  Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia , 2001, Biological Psychiatry.

[27]  James C. Vickers,et al.  Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease , 1994, Trends in Neurosciences.

[28]  W T Carpenter,et al.  Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. , 1998, The American journal of psychiatry.

[29]  D. German,et al.  Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia , 2000, Biological Psychiatry.

[30]  B. Maher,et al.  Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. , 1999, The Journal of neuropsychiatry and clinical neurosciences.

[31]  Manuel Desco,et al.  Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.

[32]  William Byne,et al.  Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients with schizophrenia. , 2003, Archives of general psychiatry.

[33]  H. Meltzer,et al.  Brain region effects of clozapine on amino acid and monoamine transmission. , 1994, The Journal of clinical psychiatry.

[34]  N. Andreasen,et al.  Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients , 1997, The Lancet.

[35]  D R Medoff,et al.  Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. , 1996, The American journal of psychiatry.

[36]  R. Murray,et al.  Neural correlates of formal thought disorder in schizophrenia: preliminary findings from a functional magnetic resonance imaging study. , 2001, Archives of general psychiatry.

[37]  S. Tsai,et al.  Reduced Regional [14C]2-Deoxyglucose Uptake in Response to Long-Term Clozapine Administration in Rats , 2001, Neuropsychobiology.

[38]  E G Jones,et al.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Andrés Santos,et al.  Cerebral metabolic patterns in chronic and recent-onset schizophrenia , 2003, Psychiatry Research: Neuroimaging.

[40]  N C Andreasen.  PET and the [15O]H2O technique, Part 2: Choosing a significance threshold. , 1996, The American journal of psychiatry.

[41]  C. Frith,et al.  Pathophysiology of ‘positive’ thought disorder in schizophrenia , 1998, British Journal of Psychiatry.

[42]  H. Holcomb,et al.  Clozapine but not Haloperidol Re-establishes Normal Task-Activated rCBF Patterns in Schizophrenia within the Anterior Cingulate Cortex , 2004, Neuropsychopharmacology.

[43]  R E Litman,et al.  The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. , 1997, Archives of general psychiatry.

[44]  F. R. Rubia Vila,et al.  SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. , 1996, American Journal of Psychiatry.

[45]  B. Pakkenberg,et al.  The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics , 1992, Schizophrenia Research.

[46]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[47]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[48]  Karl J. Friston,et al.  Combining Spatial Extent and Peak Intensity to Test for Activations in Functional Imaging , 1997, NeuroImage.

[49]  M Masellis,et al.  D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine , 2003, Molecular Psychiatry.

[50]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[51]  Mathias Schreckenberger,et al.  Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics , 1997, The Lancet.

[52]  A. Malhotra,et al.  Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. , 1996, The American journal of psychiatry.

[53]  Niels G. Waller.  The Scale for the Assessment of Negative Symptoms , 1995 .

[54]  C. Galletly,et al.  Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine , 1997, Psychiatry Research.

[55]  T. Rh.  Thought disorder in schizophrenia. , 1969 .